Prostate cancer is one of the primary genitourinary oncology diseases and is a common malignant tumor amongst men worldwide. The presence of cancer cells in the pelvic nodes represents one of the most important prognostic factors for prostate cancer recurrence and mortality, resulting in a poor survival rate and prognosis. Nonetheless, optimal management for node-positive patients still remains unclear.
Therefore, it is important to understand the role of lymph node metastasis in prostate cancer to understand how is contributes to the progression of the disease and also how to develop potential treatment and therapeutic interventions.
Lymph nodes which are located adjacent to the primary tumor are typically the first site of metastasis. Studies have demonstrated lymph node metastasis in prostate cancer typically leads to a poor prognosis and also increases the risk of biochemical recurrence. Lymph node metastasis is typically treated with radical prostatectomy with extended pelvic lymph node dissection as well as androgen deprivation therapy and radiation therapy to the patient's pelvis but more effective methods of treatment are urgently required.
Lymph node staging is vital to plan treatment and management of the disease. However, there are challenges with the diagnosis of whether lymph nodes are malignant as surgical lymph node dissection and histopathological examination is the most common technique but this is extremely invasive for patients and there is an urgent need for non-invasive methods. There have been development with imaging methods such as positron emission tomography (PET-PSMA) and magnetic resonance lymphography (MRL) which are promising alternatives to non-invasive lymph nodal staging.
The goal of this Research Topic is to understand the role of lymph nodes metastases in prostate cancer and how it influences the prognosis, initial management and progression risk of the disease.
We welcome Original Research, Review Articles, Systematic Reviews and Mini-Reviews. Research of interest includes but is not limited to:
-Surgical management of lymph node metastases
-How patients are diagnosed with lymph node metastasis
-Therapeutics and treatment available for patients with lymph node metastasis
-Molecular and cellular mechanisms of nodal metastases
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Prostate cancer is one of the primary genitourinary oncology diseases and is a common malignant tumor amongst men worldwide. The presence of cancer cells in the pelvic nodes represents one of the most important prognostic factors for prostate cancer recurrence and mortality, resulting in a poor survival rate and prognosis. Nonetheless, optimal management for node-positive patients still remains unclear.
Therefore, it is important to understand the role of lymph node metastasis in prostate cancer to understand how is contributes to the progression of the disease and also how to develop potential treatment and therapeutic interventions.
Lymph nodes which are located adjacent to the primary tumor are typically the first site of metastasis. Studies have demonstrated lymph node metastasis in prostate cancer typically leads to a poor prognosis and also increases the risk of biochemical recurrence. Lymph node metastasis is typically treated with radical prostatectomy with extended pelvic lymph node dissection as well as androgen deprivation therapy and radiation therapy to the patient's pelvis but more effective methods of treatment are urgently required.
Lymph node staging is vital to plan treatment and management of the disease. However, there are challenges with the diagnosis of whether lymph nodes are malignant as surgical lymph node dissection and histopathological examination is the most common technique but this is extremely invasive for patients and there is an urgent need for non-invasive methods. There have been development with imaging methods such as positron emission tomography (PET-PSMA) and magnetic resonance lymphography (MRL) which are promising alternatives to non-invasive lymph nodal staging.
The goal of this Research Topic is to understand the role of lymph nodes metastases in prostate cancer and how it influences the prognosis, initial management and progression risk of the disease.
We welcome Original Research, Review Articles, Systematic Reviews and Mini-Reviews. Research of interest includes but is not limited to:
-Surgical management of lymph node metastases
-How patients are diagnosed with lymph node metastasis
-Therapeutics and treatment available for patients with lymph node metastasis
-Molecular and cellular mechanisms of nodal metastases
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
